Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | ODC1 | P11926 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188179 | 1.00 | GRM2 (0.41) | GRM2GRM3SLC7A5ARG1ARG2 | |
| SCHEMBL5704696 | 1.00 | GRM2 (0.41) | GRM2GRM3SLC7A5ARG1ARG2 | |
| SCHEMBL4314004 | 0.77 | GRM2 (0.43) | GRM2GRM3SLC7A5ARG1ARG2 | |
| SCHEMBL1629778 | 0.75 | MEN1 (0.40) | GRM2GRM3ARG1ARG2ODC1 | |
| SCHEMBL11208132 | 0.74 | GABRP (0.42) | ARG1ARG2ODC1 | |
| SCHEMBL10021004 | 0.72 | GRM2 (0.37) | GRM2GRM3SLC7A5CYP2D6 | |
| SCHEMBL21821202 | 0.72 | GRM2 (0.46) | GRM2GRM3SLC7A5ARG1ARG2 | |
| SCHEMBL497762 | 0.72 | GRM2 (0.46) | GRM2GRM3SLC7A5ARG1ARG2 | |
| SCHEMBL21199502 | 0.71 | MEN1 (0.38) | ARG1ARG2ODC1CYP1A2 | |
| SCHEMBL5704692 | 0.71 | MEN1 (0.38) | ARG1ARG2ODC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024208878-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | GENEPEP (FR) | 2024-10-10 | — | — | WO | disclosed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | disclosed |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Karoyan, Philippe (FR) | 2023-09-19 | — | — | US | disclosed |
| EP-3454879-B1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2021-12-22 | — | — | EP | disclosed |
| US-20190144501-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-3454879-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-20 | — | — | EP | disclosed |
| EP-3220957-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO AN ANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2018-11-07 | — | — | EP | disclosed |
| EP-2448956-B1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NAT RECH SCIENT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-9907860-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to an anionic polypeptide for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2018-03-06 | — | — | US | disclosed |
| EP-1863832-B1 | AGE INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2012-01-04 | — | — | EP | disclosed |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | UNIVERSITE DE MONTPELLIER I (FR) | 2011-06-23 | — | — | US | disclosed |
| EP-2321277-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | Centre National de la Recherche Scientifique - CNRS (FR) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011000848-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-01-06 | — | — | WO | disclosed |
| EP-2270025-A1 | Solid phase peptide synthesis of peptide alcohols | Centre National pour la Recherche Scientifique (CNRS) (FR) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010023295-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-20080249030-A1 | Age Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-09 | — | — | US | disclosed |
| CN-101268093-A | Age inhibitors | PHARMAMENS (FR) | 2008-09-17 | — | — | CN | disclosed |
| EP-1863832-A1 | AGE INHIBITORS | Pharmamens (FR) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103274-A1 | AGE INHIBITORS | PHARMAMENS (FR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144501-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | GRM2 4742/4885GRM3 4083/4885SLC7A5 119/4885 |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | PRRC2C, VIP, PRRC2A | GRM2 4734/4885GRM3 4617/4885SLC7A5 32/4885 |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | VIP, RNASE1, ABCB11 | GRM2 4730/4885GRM3 3963/4885SLC7A5 199/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | GRM2 4730/4885GRM3 3963/4885SLC7A5 199/4885 |
| US-20080249030-A1 | Age Inhibitors | CFH, XPA, XPNPEP1 | GRM2 4789/4885GRM3 3469/4885SLC7A5 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.